Ethical Research and the Importance of Quality

This week in the Guardrail: Rigorous quality oversight isn't just a regulatory hurdle; it is the ultimate expression of respect for the safety and dignity of the patient. Read the article below.

By Michael Bronfman

The world of medicine relies on a simple promise. That promise is that every pill or treatment you take has been tested for safety and truth. This process is called clinical research. Behind every successful medicine is a long line of scientists and doctors. They work hard to ensure the data they collect is accurate. This is where the idea of quality comes into play. Quality is not just about doing a good job. In the world of pharmaceutical research, quality is the shield that protects the volunteers in medical studies. It ensures that their contribution leads to safe cures for everyone else.

What Does Quality Mean in Medical Studies

When we talk about quality in a lab or a hospital, we are talking about a set of rules. These rules are known as Good Clinical Practice. These standards make sure that the results of a study can be trusted. If a study is done poorly, the data might be wrong. If the data is wrong, then a dangerous medicine might be approved. Or a helpful medicine might be thrown away by mistake.

Quality starts with a plan. This plan is called a protocol. It lists every step the researchers will take. Following the plan exactly is the only way to keep the research ethical. When researchers cut corners, they put people at risk. High-quality research means being honest about every detail from start to finish.

Why We Must Protect the People in the Study

Clinical trials need human volunteers. These people are often called participants. They are the most important part of the research process. Without them, we would have no new ways to fight diseases. Ethical research means treating these people with respect and keeping them safe.

Quality systems are built to monitor the health of these volunteers. If a participant gets sick, the researchers must record it immediately. They must also decide if studying medicine caused the problem. This is a key part of the FDA safety guidelines that all drug companies must follow. Protecting the participant is the highest priority in any high-quality study.

The Role of Informed Consent

One of the most important parts of ethical research is informed consent. This means that a person knows exactly what will happen to them during a study before they agree to join. Quality control experts check the forms that people sign. They make sure the language is easy to understand.

A person should never feel forced to join a study. They should know the risks and the benefits. If a study is of poor quality, the researchers may not adequately explain the risks. This is a major ethical failure. By maintaining high-quality standards, we ensure that every volunteer makes a truly free choice.

Keeping Data Honest and Clear

In research, data is the evidence. It proves whether a drug works. If the data is messy or lost, the entire study fails. Ethical research requires data integrity. This means the numbers cannot be manipulated to make them look better than they are.

Companies use quality audits to assess scientists' work. They look at the original records to see if they match the final reports. If someone makes a mistake, it must be noted clearly. Hiding mistakes is unethical. When quality is high, the data is a clear mirror of what actually happened during the trial. This is essential for organizations such as the World Health Organization, which sets global health standards.

How Quality Systems Prevent Errors

Research errors can be very expensive and dangerous. A small dose error can lead to a serious problem for a patient. Quality management systems act like a safety net. They use checks and balances to catch errors before they cause harm.

For example, if a scientist is supposed to check a blood sample at a specific time, the system logs that event. If the scientist forgets, the system sends an alert. These tools help maintain a high level of accuracy. Accuracy is a form of respect for the science and the patients.

The Link Between Ethics and Quality

It is impossible to have ethical research without high quality. Think of it like building a house. Ethics is the reason you want the house to be safe for the family living there. Quality is the set of strong materials and correct measurements you use to build it. If you use weak wood, the house might fall down. In pharma research, if you use poor quality, the ethical foundation crumbles.

Regulators like the European Medicines Agency look for this link. They want to see that companies care about the truth as much as they care about profit. They ensure that every company follows the same ethical path. You can find more about these standards on the European Medicines Agency website 

The Future of Quality in Pharma

Technology is changing how we do research. We now use computers and artificial intelligence to track data. This can make quality even better. It allows us to see patterns faster. We can spot safety issues much earlier than we could in the past.

Even with new tools, the human element remains the most vital part. Doctors and nurses must still look their patients in the eye. They must remain committed to the truth. Quality is a culture that starts with people. It is a commitment to doing things the right way, even when no one is watching.

How to Tell if a Study is Ethical

If you are thinking about joining a study or just want to learn more, there are things to look for.

• Does the study have an Institutional Review Board (IRB)? This is a group that reviews the ethics of the study.

• Is the study listed on official sites like ClinicalTrials.gov? An official listing means the study is in compliance with legal quality standards.

• Are the researchers willing to answer all your questions? Openness is a sign of high quality.

Final Thoughts on Quality and Ethics

Quality in pharmaceutical research is about more than just paperwork. It is about the lives of real people. Every time a new medicine reaches the pharmacy, it is the result of thousands of hours of careful work. This work must be done with the highest level of integrity.

When we focus on quality, we protect the volunteers. We protect the scientists. Most importantly, we protect the millions of people who will use the medicine in the future. Quality is the only way to ensure that medical progress is also ethical progress. We must continue to demand high standards from every drug company and every research lab. This is how we build a healthier and safer world for everyone.

When patient safety is your North Star, compliance becomes your greatest competitive advantage. Contact Metis Consulting Services today to build a culture of quality that honors your participants and safeguards your path to market.

Active Web Links

1. FDA Clinical Trial Basics: https://clinicaltrials.panfoundation.org/

2. WHO Ethical Standards: https://www.who.int/teams/health-ethics-governance/governance/research

3. EMA Good Clinical Practice: https://www.ema.europa.eu/en/human-regulatory-overview/research-development/compliance-research-development/good-clinical-practice

4. Official Clinical Trials Registry: https://clinicaltrials.gov/

The Advantages of Bringing Pharmaceutical CMOs Back to the United States

For Metis Consulting Services, Inc. 

By Michael Bronfman

August 11, 2025

This week in the "Guard Rail," we at Metis are exploring "Reshoring" of CMOs. We can't afford to settle for anything less than a fortified, domestic, and regional pharmaceutical industry. For decades, the lure of international manufacturing offered a path of lower costs, but this road has proven to be full of potholes.

The Benefits of Bringing Pharmaceutical CMOs Back to the United States (Reshoring)

The pharmaceutical industry plays a central and critical role in public health. Every stage in the drug development and manufacturing process impacts the final quality and safety of medicines. Contract Manufacturing Organizations, known as CMOs, are third-party organizations that manufacture drugs for pharmaceutical firms. These organizations handle activities ranging from producing active pharmaceutical ingredients (API) to packaging and labeling.

Over the past several decades, a large number of pharmaceutical manufacturers have moved overseas. Let's talk about why this is happening: cost savings, reduced labor expenses, and relaxed regulatory environments often tempt companies to China and India.

There have been growing discussions lately about the benefits of bringing pharmaceutical CMOs back to the United States. The term for this movement is "reshoring." The trend to shift overseas has come with a set of challenges and risks that directly impact quality, safety, and national security. Although reshoring requires investment of all kinds, including time and workforce development, among others, it also brings a wide range of returns on those investments. These advantages include improved supply chain resilience, increased product quality, strengthened national security, job creation, and a reduction in reliance on foreign manufacturing. And isn't that what we all want?

Here, we will take a bigger look at how reshoring CMOs to the United States offers long-term benefits to both the pharmaceutical industry and the public.

Improved Supply Chain Reliability

Pharmaceutical manufacturing operates most effectively with a stable supply chain. Delays, shortages, and disruptions have serious consequences for patients' access to the drugs they need. The complexity of global supply chains is in itself a challenge that creates multiple points of vulnerability. Drugs may pass through several countries before reaching their final destination. Disruption along this path, at any point, can lead to delays or stockouts. The long, complex chain is vulnerable to myriad forms of delay, including political tensions, natural disasters, or transportation failures.

By relocating CMOs to the United States, pharmaceutical companies can reduce the number of steps involved in the supply chains. As a result, we would expect faster delivery of finished products and improved response times during public health emergencies. A domestic manufacturing base allows for greater control over production scheduling and inventory management.

During the COVID-19 pandemic, global supply chain disruptions exposed the risks of overdependence on foreign manufacturing. Not just for us here in the US, but globally. Shortages of essential medications and active pharmaceutical ingredients were rampant. A more localized supply chain could help prevent similar problems in the future.

Enhanced Quality Control and Regulatory Oversight

The United States Food and Drug Administration enforces strict regulatory standards. The manufacturers must follow detailed guidelines to ensure safety, consistency, and efficacy. When pharmaceutical companies outsource production to overseas CMOs, consistent quality and quality oversight are more challenging. Regulatory agencies often lack the same reach and oversight capabilities in other countries.

If their CMOs are located back here in the United States, companies gain better access to real-time oversight, audits, inspections, and monitoring. Regulatory compliance is easier to enforce, and deviations from quality standards can be addressed more quickly. This results in fewer product recalls, improved batch consistency, and greater confidence in the quality of the medication supply.

Patients should always be the guiding light in pharmaceutical manufacturing. They deserve safe and effective treatments. A return to domestic production would enhance quality assurance. Improving it every step of the way, from raw material sourcing to final packaging.

Stronger National Security

Pharmaceutical products are a cornerstone of national health and security. When production is concentrated overseas, vulnerabilities become more apparent. Whether it is interruptions to supply or trade restrictions, or foreign political instability, we have more challenges to the health and security. In times of crisis, foreign governments may prioritize domestic needs and restrict exports of critical medications.

Now let's look at that risk when considering essential medications such as antibiotics, vaccines, and insulin. The lack of domestic manufacturing capacity limits the nation's ability to respond to emergencies. If there is another pandemic, or there are bioterrorism threats, or a natural disaster, reshoring pharmaceutical CMOs will strengthen national security by reducing dependence on international suppliers. This will allow for faster production of essential drugs in response to urgent needs. We need to mitigate the vulnerability before any of these disasters strike. With a domestic manufacturing infrastructure in place, as a result, the United States, or even the Americas, will be able to better protect its citizens during emergencies and avoid the harmful effects of drug shortages.

Economic Growth and Job Creation

Potential for economic development is another major advantage of bringing CMOs back to the United States. The pharmaceutical industry is a sector that is growing and expanding. This vital industry can provide high-paying jobs in science, engineering, quality control, and logistics.

Local communities are economically stimulated in related industries, including transportation, utilities, and construction. Building new manufacturing facilities or expanding existing ones could create employment opportunities for both skilled and entry-level workers. As more companies invest in domestic production, entire ecosystems develop around pharmaceutical hubs. These ecosystems create long-term economic benefits that go beyond the companies themselves.

In regions facing economic decline, pharmaceutical manufacturing plants have the potential to provide a much-needed economic boost. The jobs that are created tend to have better wages and benefits than many other industries, contributing to a higher standard of living. This, in turn, creates community stability.

Increased Transparency and Accountability

Patients, providers, and regulators must know where medications are produced and under what conditions. Transparency is essential. When production is moved overseas, transparency often decreases.

Domestic manufacturing encourages greater openness. Regulatory agencies have greater ease of access to inspect facilities and review records. Companies can communicate more clearly with the public about sourcing, safety, and compliance. This builds trust between the pharmaceutical industry and the patients it serves.

Consumers are showing interest in where their medications are made. Just as people care about the origin of their food, many want to know whether their medicines are produced safely and ethically. Reshoring supports this desire for greater accountability and corporate responsibility.

Technological Advancements and Innovation

When pharmaceutical manufacturing is brought back to the United States, there is a greater opportunity for innovation. Continuous manufacturing, advanced automation, and improved quality control systems are all more likely with a chain of domestic facilities. They are more likely to adopt cutting-edge technologies. These technologies increase efficiency, reduce costs over time, and enhance product consistency.

In contrast, many overseas facilities are slower to modernize due to limited capital investment or regulatory restrictions. Reshoring CMOs allows American firms to lead in pharmaceutical technology and manufacturing science.

Collaboration is strengthened: manufacturers, research institutions, and universities work together more naturally. The exchange of knowledge and technology accelerates innovation and shortens the time needed to bring new treatments to market.

Resilience in Times of Crisis

We have seen how vulnerable the global pharmaceutical supply chain can be. Recent events have led to delays, shortages, and rising prices. When companies rely too heavily on foreign suppliers, they lose the ability to adapt quickly to changing circumstances.

Creating a network of CMOs domestically increases resilience. Manufacturers will be able to launch emergency initiatives in a timely manner. They can adjust production levels or shift resources without waiting for overseas partners. This flexibility is essential during times of national crisis.

By investing in domestic capacity now, pharmaceutical companies can ensure they are prepared for the challenges of tomorrow. Reshoring is a long-term strategy that increases preparedness and stability.

Ethical and Environmental Considerations

Ethical labor practices and environmental standards can vary widely across different countries. CMOs may or may not operate under conditions that do not align with US values. There might be extremely low wages, unsafe working conditions, or limited environmental protections.

Bringing pharmaceutical manufacturing back to the US ensures compliance with fair labor laws and environmental regulations. Companies are required to provide safer working conditions and reduce their environmental impact. And consumers, in this case, patients, are increasingly interested in how products are made. These efforts support sustainability goals and improve corporate reputation.

Ethical sourcing and responsible production practices are no longer optional. Reshoring aligns with public expectations and supports the broader goal of corporate social responsibility.

I hope that after reading this, we all can agree that the decision to bring pharmaceutical CMOs back to the United States is both strategic and responsible. Offshore manufacturing has seemed to offer short-term cost savings. At the same time, it has created long-term risks related to quality, supply chain stability, and national security.

By investing in domestic production, the pharmaceutical industry can strengthen its foundation. Advantages include more reliable supply chains, enhanced quality control, stronger national security, economic growth, technological leadership, and ethical transparency.

Reshoring is certainly not without its challenges; it requires capital investment, workforce development, and regulatory planning. The long-term benefits do outweigh the initial costs. We can deliver safer, more reliable treatments to the people who need them most by producing more of our medications closer to home. And our industry will do all of that with a smaller footprint.

As the pharmaceutical industry faces growing complexity and rising public expectations, reshoring CMOs is a powerful step toward a more secure, transparent, and innovative future. The time has come to rebuild U.S. pharmaceutical manufacturing, for both economic reasons and the health and well-being of the nation.

If you are in a position to contract your organization's CMO and would like to discuss how to reshore manufacturing, please contact us at

hello@metisconsultingservices.com

Or for more information, see our website at:

https://www.metisconsultingservices.com/

Or better yet, schedule an appointment:

https://calendly.com/sbradley-metisconsultingservices